A stylized illustration of a cylindrical cup with blue arrows and lines indicating a swirling or rotational motion inside the cup.
Briefs
 Finance
Free NewsletterPro Login

Warning: Undefined variable $stocks in /var/www/briefs.co/htdocs/wp-content/plugins/oxygen/component-framework/components/classes/code-block.class.php(133) : eval()'d code on line 448

Warning: foreach() argument must be of type array|object, null given in /var/www/briefs.co/htdocs/wp-content/plugins/oxygen/component-framework/components/classes/code-block.class.php(133) : eval()'d code on line 448

Warning: Undefined variable $funds in /var/www/briefs.co/htdocs/wp-content/plugins/oxygen/component-framework/components/classes/code-block.class.php(133) : eval()'d code on line 472

Warning: foreach() argument must be of type array|object, null given in /var/www/briefs.co/htdocs/wp-content/plugins/oxygen/component-framework/components/classes/code-block.class.php(133) : eval()'d code on line 472
/* the link was here */

Adarx files for U.S. IPO to advance RNA drugs that tune gene expression

Milena Thomas
Published Sep 4, 2026
[tts_player]
Share:
Summary:
  • Adarx Pharmaceuticals Inc. filed Friday with the U.S. Securities and Exchange Commission for an initial public offering.
  • Proceeds are slated to advance five small interfering RNA programs, including finishing Phase 2 trials for a therapy in rare renal and other diseases.
  • In May last year, Abbvie Inc. paid $335 million upfront in a collaboration that could deliver several billion dollars more if milestones are hit.

What Adarx is building and why it matters

San Diego based Adarx is developing medicines that dial gene activity up or down to tackle a range of conditions. IPO funds are earmarked for five small interfering RNA drug candidates spanning clinical and preclinical stages, including completing a mid stage Phase 2 program for a therapy in rare kidney disorders and other indications. The approach targets disease at the gene level without making permanent changes to a person's DNA or genome.

Who is backing the company

Abbvie's 2023 deal with Adarx covers programs in neuroscience, immunology and oncology, starting with a $335 million upfront payment and milestone paths that could add several billion dollars more. Major holders include OrbiMed Advisors, LAV, Chief Executive Officer Zhen Li and SR One, with OrbiMed owning 31% before the offering. In 2023, Bain Capital Life Sciences and TCGX co-led a $200 million Series C that brought in new investors BlackRock Inc., Invus, Marshall Wace and T. Rowe Price Group Inc.

When breakthrough research requires time, disciplined saving and investing still build wealth, so get the free Always Be Buying E-Book

What to watch in the deal

JPMorgan Chase & Co., Morgan Stanley, Toronto-Dominion Bank, UBS Group AG and LifeSci Capital are leading the offering. Adarx expects to list on the Nasdaq Global Market under the ticker ADRX. For everyday investors watching the space, the setup is clear enough: a mid stage program to complete, a big pharma partner already engaged and a cap table stacked with specialist healthcare funds.

Disclosure

Recent News

1 2 3 … 68

Get Market Briefs delivered to your inbox every morning for free!

No fluff. No noise. No politics. Just finance news you can read in 5 minutes.

Blogs

September 4, 2026
An Interest Rate Hike in 2026? The Fed Just Broke Its Own Script
By Nate Gregory
  • The Federal Reserve spent a year signaling cheaper money, and its new chairman just warned that an interest rate hike may be coming instead.
  • The Fed is stuck between high inflation and a weak job market, and fixing one makes the other worse.
  • Higher rates also reprice roughly a third of America's $40 trillion national debt this year, which is why Washington wants cuts so badly.
Read More
September 3, 2026
5 Passive Income Ideas That Pay You Whether You Work or Not
By Jackson Moreland
  • School teaches one formula: work, earn, spend. Stop working and the money stops, so the wheel never ends.
  • Five assets pay you without your labor - dividends, rent, interest, royalties, and the things you already own.
  • $80,000 a year of cash flow takes about $1 million invested at 8%, or roughly 20 years of $1,000 a month.
Read More
September 2, 2026
The Best Way to Invest 10k: Three Options To Transform 10K into 10 Million
By Kalbir Talwar
  • Passive investing in stocks or real estate targets around 10% a year, and time in the market matters more than the price you get in at.
  • Active investing means putting your time in alongside your money, which raises the target to roughly 20% a year and raises the risk of losing it all.
  • Investing in yourself has no ceiling, because a new skill can create a new income that no market return can match.
Read More
September 1, 2026
The Tax Write Offs the Rich Are Using in 2026 While the IRS Shrinks
By Milena Thomas
  • The 2026 tax brackets landed lower than they were headed, and the standard deduction jumped from a planned $8,350 to $16,100 for single filers.
  • New write offs for overtime, tips, seniors and car loan interest are live now, and most of them are written to expire in 2028.
  • About a third of IRS auditors have been fired, and four assets do most of the work for people who want income without a matching tax bill.
Read More
August 31, 2026
America Is Running Out of Debt Buyers. Treasury Bills Are the Government's Fix
By Nate Gregory
  • The government took in about $5 trillion in taxes in 2025 and spent about $7 trillion, and the national debt is now over $40 trillion.
  • Investors, banks, and foreign countries are all lending less to the U.S., so starting September 9 the government plans to sell more short-term treasury bills and use that cash to buy back its long-term debt.
  • Government interest rates set the floor for your mortgage, your car loan, and your credit card, and short-term Treasury ETFs like SGOV are one way investors are playing it.
Read More
August 23, 2026
How to Get the Most From Your Guideline 401k
By Nate Gregory
  • Guideline is a company that provides low-cost 401k plans, popular with small businesses and their employees.
  • A "Guideline 401k" follows the same core rules as any 401k: tax-advantaged growth, contribution limits, and often an employer match.
  • The biggest results come from capturing the full match, choosing low-cost funds, and picking Roth or traditional to fit your situation.
Read More
August 23, 2026
Principal 401k: What to Know About Your Plan
By Cierra Seay
  • Principal is one of many companies that manage workplace 401k plans, so a "Principal 401k" is simply a 401k where Principal is the provider.
  • The rules of a 401k are the same no matter who runs it: pre-tax or Roth contributions, tax-advantaged growth, and often an employer match.
  • The biggest wins come from grabbing the full match, picking low-cost funds, and knowing whether Roth or traditional fits you.
Read More
August 23, 2026
What a Tariff Dividend Means for Your Money
By Jackson Moreland
  • A "tariff dividend" is the idea of taking money the government collects from tariffs and paying some of it back to citizens.
  • To judge the idea, you first need to know what a tariff is: a tax on imported goods, usually paid by the companies bringing them in.
  • Tariffs ripple through prices, businesses, and your investments, so the smart move is understanding those ripples, not just the headline.
Read More
August 23, 2026
No Tax on Overtime: How Overtime Pay Is Taxed
By Milena Thomas
  • "No tax on overtime" refers to a tax break that lets certain workers deduct some overtime pay, lowering the income they get taxed on.
  • A deduction does not mean overtime is truly tax-free. It means part of that pay is subtracted before your tax is figured.
  • The bigger money lesson: how you earn money changes how it is taxed, and investors often get the friendliest treatment of all.
Read More
August 23, 2026
Reading the Silver Price Forecast for 2026
By Nate Gregory
  • Nobody can honestly promise a specific silver price for 2026. Any exact number is a guess, so treat forecasts as opinions, not facts.
  • Silver is unusual because it is both a precious metal and an industrial metal, so its price answers to two very different forces.
  • Instead of chasing a forecast, learn the drivers - inflation, interest rates, recession fear, and industrial demand - so you can judge any prediction yourself.
Read More
1 2 3 … 26
Share via
Facebook
X (Twitter)
LinkedIn
Mix
Pinterest
Bluesky
Tumblr
Skype
Buffer
Pocket
VKontakte
Parler
Xing
Reddit
Line
Flipboard
MySpace
Delicious
Amazon
Digg
Evernote
Blogger
LiveJournal
Baidu
MeWe
NewsVine
Yummly
Yahoo
WhatsApp
Viber
SMS
Telegram
Facebook Messenger
Like
Email
Print
Copy Link
Copy link
CopyCopied